Sequenom nearly doubles Q2 sales; Quest teams up with the NFL's Giants;

@FierceMedDev: Boston Scientific's Q2 reflects both stagnation and promising growth. Article | Follow @FierceMedDev

@MarkHFierce: We are entering our last week for FMD F15 nominations. Get yours in now. Submission form | Follow @MarkHFierce

@DamianFierce: Roche posted only slight diagnostics growth in H1, as a diabetes slump weighed down testing sales. Story | Follow @DamianFierce

 @MichaelGFierce: From FierceDrugDelivery.com: Novaliq secures CE mark for OTC drop to treat dry eye. Report | Follow @MichaelGFierce

> Boston Scientific ($BSX) won FDA clearance for its Rhythmia cardiac mapping system, part of the company's efforts to expand in electrophysiology. Story

> Varian Medical ($VAR) posted $726 million in sales last quarter, a 3% increase over the same period last year. Results

> Sequenom ($SQNM) boosted sales by 91% in the second quarter, bringing in $34.9 million from its non-invasive prenatal tests. More

> Dialysis outfit NxStage Medical ($NXTM) recorded $65.5 million in sales last quarter, an 11% jump over the previous year, and the company reduced its net loss from $5.1 million to $3.4 million. Item

> Meridian Bioscience landed $47.1 million in sales last quarter, 12% above the same period last year. News

> While Quest Diagnostics ($DGX) is struggling with reimbursement cutbacks and declining revenue, the company found enough cash to sponsor the New York Giants' East Rutherford, NJ, practice facility. Article

Biotech News

@FierceBiotech: ICYMI: Sanofi returns to the crowdsourcing well for diabetes app. Article | Follow @FierceBiotech

@RyanMFierce: Stem cell pioneer's biotech startup raises $46M in IPO. Report | Follow @RyanMFierce

@EmilyMFierce: Inovio Pharma DNA cancer vaccine causes tumor death in animals. Article | Follow @EmilyMFierce

> AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin. Report

> Johnson & Johnson, Vertex execs speak up for 'breakthrough' status in Washington. Article

> Teva, Lonza end biosimilars joint venture as the copycat crowd thins. News

> Industry Voices: mRNA-Based Therapies--Blueprints for Therapeutics. Feature

Pharma News

@FiercePharma: FTC eyeing new patent deals for pay-for-delay action in wake of SCOTUS ruling. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: Wednesday at Fierce, starring Neuron, Measles, Tuberculosis, MRSA and E. coli. Image | Follow @CarlyHFierce

> GlaxoSmithKline to pay states $229M to wrap Avandia suits, other claims. Article

> Roche's 'blowout' cancer launches help fuel 10% profits hike. More

> Biogen's Tecfidera races past estimates with $192M in Q2 sales. Report

Pharma Manufacturing News

@EricPFierce: CMO Exela looks to get $1 million USDA loan to help expand plant, add jobs. Story | Follow @EricPFierce

> Fresenius Kabi Indian plant accused of manipulating data. More

> Lonza phasing out troubled Massachusetts biologics plant. Report

> FMC spends $345M for Epax omega-3 plants. Item

> FDA excoriates Wockhardt over missing records, standing urine. Story

> GSK looks to manufacturing to reduce vaccine costs. Article

Vaccines News

> Indian ethics journal pushes for ban on Crucell vaccine. Item

> Serum targets Merck, Sanofi stronghold with TB vax deal. More

> U.K. rejection of Bexsero hits Novartis vaccine unit. Report

> Lupin eyes vaccine growth after in-licensing Merck shot. News

> GSK planning joint venture to tap into Chinese vaccine demand. Article

> Study suggests GSK's Cervarix can prevent throat cancer. Story

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.